Active substance
Results for the substance teclistamab
2 results
About this active substance
Teclistamab is a bispecific antibody used for the treatment of relapsed or refractory multiple myeloma. It works by binding T cells to myeloma cells, stimulating the immune system to destroy cancer cells.
The medication is administered via subcutaneous injection, as directed by a doctor. It is important for patients to be closely monitored to prevent severe adverse reactions, such as cytokine release syndrome.
Patients should be aware of potential side effects, such as fever, fatigue, or nausea. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as cytokine release syndrome or serious infections may occur. Patients should be informed of these risks before starting treatment.
The medication is administered via subcutaneous injection, as directed by a doctor. It is important for patients to be closely monitored to prevent severe adverse reactions, such as cytokine release syndrome.
Patients should be aware of potential side effects, such as fever, fatigue, or nausea. It is important to inform the doctor of any unusual symptoms.
Common side effects include fever, fatigue, nausea, and decreased blood cell counts. In rare cases, severe reactions such as cytokine release syndrome or serious infections may occur. Patients should be informed of these risks before starting treatment.